CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 467,443	$ 80,428
Marketable securities	197,410	282,046
Interest receivable	534	682
Accounts receivable	5,618	36,909
Prepaid expenses and other current assets	8,395	5,408
Total current assets	679,400	405,473
Marketable securities, non-current	0	21,832
Property and equipment, net	33,907	29,926
Intangible assets	53,219	53,156
Goodwill	39,318	39,273
Operating lease right-of-use assets	73,501	77,289
Other non-current assets	13,814	9,067
Non-current restricted cash	1,500	1,500
Total assets	894,659	637,516
Current liabilities:
Accounts payable and accrued liabilities	19,221	17,556
Accrued compensation and employee benefits	13,332	13,605
Deferred revenues	61,389	38,711
Total current liabilities	93,942	69,872
Deferred revenues, non-current	237,644	81,432
Long-term portion of lease liabilities	39,234	41,192
Deferred income tax	6,578	6,570
Other non-current liabilities	6,055	5,711
Total liabilities	383,453	204,777
Commitments and contingencies
Stockholders' equity:
Preferred stock	0	0
Common stock	1,410	1,160
Additional paid-in capital	1,247,527	1,090,828
Accumulated deficit	(735,827)	(656,985)
Accumulated other comprehensive loss	(1,653)	(2,449)
Total Sangamo Therapeutics, Inc. stockholders' equity	511,457	432,554
Non-controlling interest	(251)	185
Total stockholders' equity	511,206	432,739
Total liabilities and stockholders' equity	$ 894,659	$ 637,516